Logo Logo
Help
Contact
Switch Language to German

Houben-Wilkes, Sarah; Jörres, Rudolf A. ORCID logoORCID: https://orcid.org/0000-0002-9782-1117; Bals, Robert; Franssen, Frits M. E.; Gläser, Sven; Holle, Rolf; Karch, Annika; Koch, Armin; Magnussen, Helgo; Obst, Anne; Schulz, Holger; Spruit, Martijn A.; Wacker, Margarethe E.; Welte, Tobias; Wouters, Emiel F. M.; Vogelmeier, Claus and Watz, Henrik (2017): Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. In: American Journal of Respiratory and Critical Care Medicine, Vol. 195, No. 2: pp. 189-197

Full text not available from 'Open Access LMU'.

Abstract

Rationale: Knowledge about the prevalence of objectively assessed peripheral artery disease (PAD) and its clinical relevance in patients with chronic obstructive pulmonary disease (COPD) is scarce. Objectives: We aimed to: (1) assess the prevalence of PAD in COPD compared with distinct control groups;and (2) study the association between PAD and functional capacity as well as health status. Methods: The ankle-brachial index was used to diagnose PAD (ankle-brachial index <= 0.9). The 6-minute-walk distance, health status (St. George's Respiratory Questionnaire), COPD Assessment Test, and EuroQol-5-Dimensions were assessed in patients enrolled in the German COPD and Systemic Consequences-Comorbidities Network cohort study. Control groups were derived from the Study of Health in Pomerania. Measurements and Main Results: A total of 2,088 patients with COPD (61.1% male;mean [SD] age, 65.3 [8.2] years, GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5, and 10.5%, respectively) were included, of which 184 patients (8.8%;GOLD stage I-IV: 5.1, 7.4, 11.1, and 9.5%, respectively, vs. 5.9% in patients with GOLD stage 0 in the COPD and Systemic Consequences-Comorbidities Network) had PAD. In the Study of Health in Pomerania, PAD ranged from 1.8 to 4.2%. Patients with COPD with PAD had a significantly shorter 6-minute-walk distance (356 [108] vs. 422 [103] m, P < 0.001) and worse health status (St. George's Respiratory Questionnaire: 49.7 [20.1] vs. 42.7 [20.0] points, P < 0.001;COPD Assessment Test: 19.6 [7.4] vs. 17.9 [7.4] points, P = 0.004;EuroQol-5-Dimensions visual analog scale: 51.2 [19.0] vs. 57.2 [19.6], P < 0.001). Differences remained significant after correction for several confounders. Conclusions: In a large cohort of patients with COPD, 8.8% were diagnosed with PAD, which is higher than the prevalence in control subjects without COPD. PAD was associated with a clinically relevant reduction in functional capacity and health status.

Actions (login required)

View Item View Item